biomerica.png
Biomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™
12 mai 2022 08h19 HE | Biomerica, Inc.
- Attaining CE Mark is a major step toward commercialization – - World Health Organization (WHO) lists H. pylori among the 16 antibiotic-resistant bacteria that pose the greatest threat to human...
biomerica.png
Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population
26 avr. 2022 08h19 HE | Biomerica, Inc.
Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection H. pylori infection is also a major...
Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Publication, "Gastrin Vaccine Alone and in Combination with an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer" in Frontiers in Oncology
06 déc. 2021 10h00 HE | Cancer Advances Inc
DURHAM, N.C., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces a new publication in...
22157.jpg
Tyrokinse Kinase Inhibitors in the Global Oncology Market 2021: Market Leaders by Indication and Product
05 nov. 2021 05h58 HE | Research and Markets
Dublin, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The "Oncology Markets for Tyrokinse Kinase Inhibitors" report has been added to ResearchAndMarkets.com's offering. Traditional cancer therapy has focused...
Zai Lab logo .png
Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
04 oct. 2021 07h30 HE | Zai Lab Limited
Final data collection is expected in the first half of 2022 SHANGHAI and St. Helier, JERSEY, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative...
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
16 sept. 2021 02h45 HE | MacroGenics, Inc.
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A78% of patients had tumor...
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
12 sept. 2021 19h00 HE | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
22157.jpg
Global $196.96 Bn Oncology Devices Market to 2025 & 2030: Major Players are Eckert & Ziegler BEBIG, Oncura, GE, Medtronic, Varian Medical Systems, Elekta, Theragenics, Accuray, and Roche Diagnostics
20 août 2021 06h08 HE | Research and Markets
Dublin, Aug. 20, 2021 (GLOBE NEWSWIRE) -- The "Oncology Devices Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The global...
Logo.png
The Plethora of Clinical Trials Explore Gastric Cancer Treatments: A Status Review by DelveInsight
04 mai 2021 20h00 HE | DelveInsight Business Research LLP
Los Angeles, USA, May 04, 2021 (GLOBE NEWSWIRE) -- The Plethora of Clinical Trials Explore Gastric Cancer Treatments: A Status Review by DelveInsight  The Gastric Cancer pipeline will allow the...
logo-alt.png
Global Rare Disease Market is estimated to be US$ 547.5 billion by 2030 with a CAGR of 13.1% during the forecast period - by PMI
24 févr. 2021 10h35 HE | PMI
Covina CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Global Rare Disease Market accounted for US$ 161.4 billion in 2020 and is estimated to be US$ 547.5 billion by 2030 and is anticipated to register a CAGR...